1
|
Ur Rehman A, Wang Z, Qin Q, Zhang X, Akhtar A, Liu H, Mao B, Khan N, Tang L, Li X. Enhancing antitumor immunity and achieving tumor eradication with IL11RA mRNA immunotherapy. Int Immunopharmacol 2024; 134:112205. [PMID: 38718659 DOI: 10.1016/j.intimp.2024.112205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Revised: 04/30/2024] [Accepted: 05/02/2024] [Indexed: 06/03/2024]
Abstract
Current methods for delivering genes to target tumors face significant challenges, including off-target effects and immune responses against delivery vectors. In this study, we developed a novel approach using messenger RNA (mRNA) to encode IL11RA for local immunotherapy, aiming to harness the immune system to combat tumors. Our research uncovered a compelling correlation between IL11RA expression and CD8 + T cell levels across multiple tumor types, with elevated IL11RA expression correlating with improved overall survival. Examination of the Pan-Cancer Atlas dataset showed a significant reduction in IL11RA expression in various cancer types compared to normal tissue, raising questions about its potential role in tumorigenesis. To achieve efficient in vivo expression of IL11RA, we synthesized two mRNA sequences mimicking the wild-type protein. These mRNA sequences were formulated and capped to ensure effective delivery, resulting in robust expression within tumor sites. Our investigation into IL11RA mRNA therapy demonstrated its effectiveness in controlling tumor growth when administered both intratumorally and intravenously in mouse models. Additionally, IL11RA mRNA treatment significantly stimulated the expansion of CD8 + T cells within tumors, draining lymph nodes, and the spleen. Transcriptome analysis revealed distinct transcriptional patterns associated with T cell functions. Using multiple deconvolution algorithms, we found substantial infiltration of CD8 + T cells following IL11RA mRNA treatment, highlighting its immunomodulatory effects within the tumor microenvironment. In conclusion, IL11RA mRNA therapy presents a promising strategy for tumor regression with potential immunomodulatory effects and clinical implications for improved survival outcomes.
Collapse
Affiliation(s)
- Adeel Ur Rehman
- Clinical Molecular Medicine Testing Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China; Key Laboratory of Major Brain Disease and Aging Research (Ministry of Education), Institute for Brain Science and Disease, Chongqing Medical University, Chongqing 400016, China.
| | - Zhihuai Wang
- Department of General Surgery, Changzhou No.2 People's Hospital Affiliated with Nanjing Medical University, Changzhou, Jiangsu, 213000, China
| | - Qianshan Qin
- Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, 215123, China
| | - Xiaojing Zhang
- Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, 215123, China
| | - Aleena Akhtar
- Clinical Molecular Medicine Testing Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Hanyang Liu
- Charité‑University Medical Center, Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molecular Cancer Research Center, D‑13353 Berlin, Germany
| | - Binli Mao
- Clinical Molecular Medicine Testing Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Naveed Khan
- Graduate School of Green-Bio Science, Kyung Hee University, Yongin 17104, Korea
| | - Liming Tang
- Department of General Surgery, Changzhou No.2 People's Hospital Affiliated with Nanjing Medical University, Changzhou, Jiangsu, 213000, China
| | - Xiaosong Li
- Clinical Molecular Medicine Testing Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China; Key Laboratory of Major Brain Disease and Aging Research (Ministry of Education), Institute for Brain Science and Disease, Chongqing Medical University, Chongqing 400016, China.
| |
Collapse
|
2
|
Cao L, Yang W, Zhao X, Chen Z. Diagnostic and prognostic value of circulating tumor cells in renal cell cancer: A systematic review and meta-analysis. Asian J Surg 2024:S1015-9584(24)00259-8. [PMID: 38378410 DOI: 10.1016/j.asjsur.2024.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 01/11/2024] [Accepted: 02/07/2024] [Indexed: 02/22/2024] Open
Abstract
Renal cell carcinoma (RCC) is a type of tumor with high morbidity and recurrence rates. The application of circulating tumor cells (CTCs) in RCC remains controversial. Hence, we performed a meta-analysis to elucidate the diagnostic and prognostic value of CTCs in RCC. To obtain a precise conclusion, a systematic search was conducted in Pubmed, Cochrane Database, Embase and Web of Science up to Dec 01, 2022. We also further identified the references in relevant studies. The diagnostic accuracy variables (sensitivity, specificity) and odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were used to access precise of CTCs and relationship between CTCs and disease stages, respectively. Heterogeneity test, sensitivity analysis, meta-regression and publishing bias were also applied. A total of 12 studies involving 767 patients were considered to be included in the final meta-analysis. The results revealed that the overall sensitivity, specificity of CTC detection in RCC were 45% (95%CI, 32-60%) and 99% (95%CI, 97-100%), respectively. In subgroup analysis, diagnostic sensitivity of CTCs in clear cell renal cell carcinoma (ccRCC) (69%, 95%CI; 50-88%) was significantly higher than other RCC subtypes (34%, 95%CI; 21-48%) (p<0.05). Meanwhile, advanced diseases (stage III-IV) were more likely to find CTCs than localized diseases (stage I-II) (OR, 2.29; 95%CI, 1.37-3.83; p = 0.002). This systematic review and meta-analysis demonstrated that CTC detection could be considered as a promising auxiliary diagnostic and staging method for RCC, especially ccRCC subtype. Meanwhile, the presence of cytokeratin-positive CTCs is highly likely associated with increased risk of poor prognosis in RCC.
Collapse
Affiliation(s)
- Liang Cao
- Department of Urology, The First People's Hospital of Neijiang, No. 1866 Han'an Avenue, Shizhong, Neijiang, 641000, China.
| | - Wenming Yang
- Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Chengdu, 610041, China
| | - Xiang Zhao
- Department of Otolaryngology, The First People's Hospital of Neijiang, No. 1866 Han'an Avenue, Shizhong, Neijiang, 641000, China
| | - Zhibin Chen
- Department of Urology, The First People's Hospital of Neijiang, No. 1866 Han'an Avenue, Shizhong, Neijiang, 641000, China
| |
Collapse
|
3
|
Rehman AU, Olsson PO, Akhtar A, Padhiar AA, Liu H, Dai Y, Gong Y, Zhou Y, Khan N, Yang H, Tang L. Systematic molecular analysis of the human secretome and membrane proteome in gastrointestinal adenocarcinomas. J Cell Mol Med 2022; 26:3329-3342. [PMID: 35488454 PMCID: PMC9189341 DOI: 10.1111/jcmm.17338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 03/12/2022] [Accepted: 04/09/2022] [Indexed: 11/27/2022] Open
Abstract
The human secretome and membrane proteome are a large source of cancer biomarkers. Membrane‐bound and secreted proteins are promising targets for many clinically approved drugs, including for the treatment of tumours. Here, we report a deep systematic analysis of 957 adenocarcinomas of the oesophagus, stomach, colon and rectum to examine the cancer‐associated human secretome and membrane proteome of gastrointestinal tract adenocarcinomas (GIACs). Transcriptomic data from these GIACs were applied to an innovative majority decision‐based algorithm. We quantified significantly expressed protein‐coding genes. Interestingly, we found a consistent pattern in a small group of genes found to be overexpressed in GIACs, which were associated with a cytokine–cytokine interaction pathway (CCRI) in all four cancer subtypes. These CCRI associated genes, which spanned both one secretory and one membrane isoform were further analysed, revealing a putative biomarker, interleukin‐1 receptor accessory protein (IL1RAP), which indicated a poor overall survival, a positive correlation with cancer stemness and a negative correlation with several kinds of T cells. These results were further validated in vitro through the knockdown of IL1RAP in two human gastric carcinoma cell lines, which resulted in a reduced indication of cellular proliferation, migration and markers of invasiveness. Following IL1RAP silencing, RNA seq results showed a consistent pattern of inhibition related to CCRI, proliferation pathways and low infiltration of regulatory T cells (Tregs) and CD8 naive cells. The significance of the human secretome and membrane proteome is elucidated by these findings, which indicate IL1RAP as a potential candidate biomarker for cytokine‐mediated cancer immunotherapy in gastric carcinoma.
Collapse
Affiliation(s)
- Adeel Ur Rehman
- Department of General Surgery, Changzhou No. 2 People's Hospital affiliated with Nanjing Medical University, Changzhou, China
| | - Per Olof Olsson
- UAE Biotech Research Center, Abu Dhabi, United Arab Emirates
| | | | - Arshad Ahmed Padhiar
- Department of Ecology and Evolutionary Biology, University of Connecticut, Storrs, Connecticut, USA
| | - Hanyang Liu
- Charité-University Medical Center, Department of Hematology, Oncology and Tumor Immunology, Virchow Campus, and Molecular Cancer Research Center, Berlin, Germany
| | - Yi Dai
- Department of General Surgery, Changzhou No. 2 People's Hospital affiliated with Nanjing Medical University, Changzhou, China
| | - Yu Gong
- Department of General Surgery, Changzhou No. 2 People's Hospital affiliated with Nanjing Medical University, Changzhou, China
| | - Yan Zhou
- Department of General Surgery, Changzhou No. 2 People's Hospital affiliated with Nanjing Medical University, Changzhou, China
| | - Naveed Khan
- CAS-MPG Partner Institute for Computational Biology, Shanghai Institute of Biological Sciences, University of Chinese Academy of Science, Chinese Academy of Science, Shanghai, China
| | - Haojun Yang
- Department of General Surgery, Changzhou No. 2 People's Hospital affiliated with Nanjing Medical University, Changzhou, China
| | - Liming Tang
- Department of General Surgery, Changzhou No. 2 People's Hospital affiliated with Nanjing Medical University, Changzhou, China
| |
Collapse
|
4
|
Clinicopathologic Analysis of Cathepsin B as a Prognostic Marker of Thyroid Cancer. Int J Mol Sci 2020; 21:ijms21249537. [PMID: 33333840 PMCID: PMC7765333 DOI: 10.3390/ijms21249537] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Revised: 12/03/2020] [Accepted: 12/10/2020] [Indexed: 12/27/2022] Open
Abstract
Thyroid cancer incidence has increased worldwide; however, investigations of thyroid cancer-related factors as potential prognosis markers remain insufficient. Secreted proteins from the cancer secretome are regulators of several molecular mechanisms and are, thereby, ideal candidates for potential markers. We aimed to identify a specific factor for thyroid cancer by analyzing the secretome from normal thyroid cells, papillary thyroid cancer (PTC) cells, and anaplastic thyroid cancer cells using mass spectrometry (MS). Cathepsin B (CTSB) showed highest expression in PTC cells compared to other cell lines, and CTSB levels in tumor samples were higher than that seen in normal tissue. Further, among thyroid cancer patients, increased CTSB expression was related to higher risk of lymph node metastasis (LNM) and advanced N stage. Overexpression of CTSB in thyroid cancer cell lines activated cell migration by increasing the expression of vimentin and Snail, while its siRNA-mediated silencing inhibited cell migration by decreasing vimentin and Snail expression. Mechanistically, CTSB-associated enhanced cell migration and upregulation of vimentin and Snail occurred via increased phosphorylation of p38. As our results suggest that elevated CTSB in thyroid cancer induces the expression of metastatic proteins and thereby leads to LNM, CTSB may be a good and clinically relevant prognostic marker.
Collapse
|